Literature DB >> 12063159

Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs.

Gina Browne1, Meir Steiner, Jacqueline Roberts, Amiram Gafni, Carolyn Byrne, Edward Dunn, Barbara Bell, Michael Mills, Lori Chalklin, David Wallik, James Kraemer.   

Abstract

BACKGROUND: There is little information on the long-term effects and costs of a combination of Sertraline and interpersonal psychotherapy (IPT) for the treatment of dysthymia in primary care.
METHODS: In a single-blind, randomized clinical trial, 707 adults (18-74 years of age inclusive) with DSM-IV dysthymic disorder, with or without past and/or current major depression, as an acute or chronic episode, in a community-based primary care practice in Ontario, Canada, were randomized to treatment with either Sertraline alone (50-200 mg), or IPT alone (10 sessions), or Sertraline plus IPT combined. In the acute treatment phase (first 6 months) all groups received full active treatment. This was followed by an additional 18-month naturalistic follow-up phase. Subjects were assessed for effectiveness of treatment in reducing depressive symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) at 6 months and twice again during the 18-month follow-up by blind independent observers. Treatment costs and subjects' use of other health and social services were also investigated.
RESULTS: At 6 months, 586 subjects completed the MADRS questionnaire. There was a significant difference (P=0.025) in mean MADRS scores: 14.3 (Group I); 14.9 (Group II); 16.8 (Group III), using analysis of covariance. Response (40% improvement) rates were 60.2% for Sertraline alone, 46.6% for IPT alone, and 57.5% for Sertraline augmented by IPT (P=0.02). At 2 years, 525 subjects were retained for follow-up. There was no statistically significant difference between Sertraline alone and Sertraline plus IPT in symptom reduction. However, both were more effective than IPT alone in reducing depressive symptoms (P=0.03). There was a statistically significant difference between groups in costs for use of health and social services. The IPT treatment groups had the lower costs for use of health and social services.
CONCLUSIONS: Sertraline or Sertraline plus IPT was more effective than IPT alone after 6 months. Over the long term (2 years), all three treatments provide reasonably effective treatment for reducing symptoms of dysthymia, but Sertraline or combining Sertraline with IPT is more effective than IPT alone. Of these two more effective treatments, subjects in the Sertraline plus IPT group had less health and social service costs by $480 per person over 2 years. These findings underscore the effects of combining pharmacotherapy and psychotherapy and the economic value of this more comprehensive treatment of dysthymia in primary care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063159     DOI: 10.1016/s0165-0327(01)00343-3

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  29 in total

Review 1.  Effectiveness of psychotherapeutic, pharmacological, and combined treatments for chronic depression: a systematic review (METACHRON).

Authors:  Levente Kriston; Alessa von Wolff; Lars Hölzel
Journal:  BMC Psychiatry       Date:  2010-11-23       Impact factor: 3.630

Review 2.  A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders.

Authors:  Marcelo Feijo de Mello; Jair de Jesus Mari; Josue Bacaltchuk; Helen Verdeli; Richard Neugebauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

3.  [Psychotherapy in primary care: presentation of a case of somatomorphic disorder treated with interpersonal therapy].

Authors:  Francisca Guerra Cabrera; María Diéguez Porres
Journal:  Aten Primaria       Date:  2011-03-04       Impact factor: 1.137

4.  A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression.

Authors:  Pim Cuijpers; Hisashi Noma; Eirini Karyotaki; Christiaan H Vinkers; Andrea Cipriani; Toshi A Furukawa
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

5.  Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults.

Authors:  Katja Machmutow; Ramona Meister; Alessa Jansen; Levente Kriston; Birgit Watzke; Martin Christian Härter; Sarah Liebherz
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

6.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

7.  Improving work outcomes of dysthymia (persistent depressive disorder) in an employed population.

Authors:  David A Adler; Debra Lerner; Zachary L Visco; Annabel Greenhill; Hong Chang; Elina Cymerman; Francisca Azocar; William H Rogers
Journal:  Gen Hosp Psychiatry       Date:  2015-04-08       Impact factor: 3.238

Review 8.  [Inpatient treatment of depression. Should one combine psychotherapy and drugs?].

Authors:  T J Huber
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

9.  Impact of a parent-based interdisciplinary intervention for mothers on adjustment in children newly diagnosed with cancer.

Authors:  David A Fedele; Stephanie E Hullmann; Mark Chaffin; Carole Kenner; Mark J Fisher; Katherine Kirk; Angelica R Eddington; Sean Phipps; Rene Y McNall-Knapp; Larry L Mullins
Journal:  J Pediatr Psychol       Date:  2013-03-07

Review 10.  [Affective disorders. The significance of psychotherapeutic approaches].

Authors:  M Berger; E L Brakemeier; C Klesse; E Schramm
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.